Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the outcome of Board Meeting of the Company held ....
BAYERCROP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bayer CropScience's Board approved its unaudited financial results for the quarter and nine months ended December 31, 2025. Q3 revenue from operations rose to ₹11,062 million from ₹10,574 million a year ago, while nine-month revenue came in at ₹45,742 million versus ₹44,270 million. Profit after tax for the quarter jumped sharply to ₹957 million (from ₹342 million in Q3 FY25), and stood at ₹5,271 million for the nine months versus ₹4,247 million earlier. Profit before tax for the quarter was ₹1,130 million. The statutory auditor Deloitte Haskins & Sells LLP issued an unqualified limited review report with no qualifications. The company noted that its agri-care business is seasonal, so quarterly figures are not necessarily representative of full-year performance. No new exceptional items or audit concerns were flagged.
Strong sequential and year-on-year recovery in profits after tax signals a healthy quarter for shareholders, though the company cautions that results are seasonal and Q3 alone should not be extrapolated to the full year. Clean auditor review supports confidence in the reported numbers.